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Abstract: Immune checkpoint inhibitors (ICIs) that target the programmed death 1 receptor (anti–
programmed cell death 1 [PD-1] therapy) have ushered in a new era of cancer therapy. However, their
application has been curtailed by serious immune-related adverse events (irAEs), such as colitis, pneu-
monitis, and myocarditis, that remain largely unpredictable. Although the use of tumor mutational
burden (TMB) as a biomarker for expected therapy response has been advocated,1 a similar parame-
ter for irAEs is lacking. In an attempt to fill this clinically relevant knowledge gap, we investigated
the association between irAEs reported during anti–PD-1 therapy and TMB by comparing large-scale
surveillance data of irAEs with the median TMB across multiple cancer types. Methods We retrieved
postmarketing data of adverse events from the US Food and Drug Administration Adverse Event Report-
ing System (FAERS) from July 1, 2014, to March 31, 2019. According to the ethics committee policy of
the EKOS (Ethikkommission Ostschweiz, Switzerland), this study was exempt from ethical review be-
cause all analyzed datasets are deidentified and publicly available. We considered only reports for which
the anti–PD-1 agents nivolumab or pembrolizumab were the suspected cause of adverse events. Anti–PD-
1 and anti-cytotoxic T-lymphocyte–associated protein 4 combination treatment was excluded. Closely
related indications were aggregated to unified terms; for example, “malignant melanoma” was aggregated
to “melanoma.” To limit our analysis to irAEs, we filtered terms to match broadly accepted diagnoses
that were outlined in peer-reviewed irAE management guidelines. The median TMB in tumor tissue
was obtained from previously published comprehensive genomic profiling.2,3 Lastly, we only considered
cancers for which there were at least 100 cases of adverse events during anti–PD-1 therapy reported in
FAERS. To assess the risk of a patient developing any irAE, we estimated reporting odds ratios (RORs)
by comparing the odds of reporting these irAEs rather than others for the anti–PD-1 agents with the
odds for all other drugs in the database, which represents standard practice for quantitative analyses of
data in FAERS and similar databases.4 Results Our search strategy identified a total of 47 304 adverse
events (AEs) in 16 397 patients reported as treated with anti–PD-1 monotherapy for 19 different cancer
types. Of these patients, 3661 had at least 1 irAE (22.3%; 95% CI, 21.7-23.0). The comparator group
comprised 16 411 749 AE reports from 5 160 064 patients. Our analysis revealed a significant positive
correlation between the ROR of reporting an irAE during anti–PD-1 therapy and the corresponding
TMB across multiple cancer types, with a higher ROR of irAE associated with a higher median number
of coding somatic mutations per megabase of DNA (Figure; Pearson correlation coefficient R = 0.704;
P < .001). The correlation coefficient suggests that 50% of the differences in the irAE risk across can-
cer types may be attributed to the TMB. Discussion Our analysis indicates that cancers with a high
TMB, such as melanoma and non–small cell lung cancer, are associated with a higher irAE ROR during
anti–PD-1 therapy, strongly suggesting that these cancers are associated with a higher risk of irAEs than
cancers with a low TMB. A possible explanation for this finding may be the different neoantigenic load
across cancer types. Additionally, studies have shown that T cells that react against a neoantigen can
crossreact against the corresponding wild-type protein.5 Another contributing mechanism may be anti-
gen spreading, where tumor cell death releases antigens, including neoantigens, that prime lymphocytes
against the wild-type antigens in healthy tissue. Given the results of the analysis, we propose that the
association between irAEs and improved response to anti–PD-1 treatment are linked via an underlying
neoantigenic potential that stems from a high TMB. A limitation of the study is the use of spontaneous
reports for indirectly measuring the risk of irAE. Furthermore, patients with cancers with a high TMB
may receive a longer course of anti–PD-1 treatment. However, most irAEs reported during anti–PD-1
therapy develop within the first few weeks of treatment.6 This finding suggests that therapy duration is
unlikely to influence the statistical outcome. In conclusion, a high TMB may be a useful biomarker for
assessing patients’ risk of irAEs during anti–PD-1 therapy, which has particular relevance for vulnerable
patient groups.
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Association Between Immune-Related Adverse
Events During Anti–PD-1 Therapy and Tumor
Mutational Burden
Immune checkpoint inhibitors (ICIs) that target the pro-
grammed death 1 receptor (anti–programmed cell death 1
[PD-1] therapy) have ushered in a new era of cancer therapy.
However, their application has been curtailed by serious im-
mune-related adverse events
(irAEs), such as colitis, pneu-
monitis,andmyocarditis, that
remain largely unpredictable. Although the use of tumormu-
tational burden (TMB) as a biomarker for expected therapy re-
sponse has been advocated,1 a similar parameter for irAEs is
lacking. In an attempt to fill this clinically relevant knowl-
edge gap, we investigated the association between irAEs re-
portedduring anti–PD-1 therapyandTMBbycomparing large-
scale surveillance data of irAEs with the median TMB across
multiple cancer types.
Methods |We retrieved postmarketing data of adverse events
from theUSFoodandDrugAdministrationAdverseEventRe-
porting System (FAERS) from July 1, 2014, to March 31, 2019.
According to the ethics committee policy of the EKOS
(Ethikkommission Ostschweiz, Switzerland), this study was
exempt fromethical review because all analyzed datasets are
deidentifiedandpubliclyavailable.Weconsideredonly reports
for which the anti–PD-1 agents nivolumab or pembrolizumab
were thesuspectedcauseofadverseevents.Anti–PD-1andanti-
cytotoxic T-lymphocyte–associated protein 4 combination
treatment was excluded. Closely related indications were
aggregated to unified terms; for example, “malignant
melanoma”wasaggregatedto“melanoma.”Tolimitouranalysis
to irAEs,we filtered termstomatchbroadlyaccepteddiagnoses
that were outlined in peer-reviewed irAE management
guidelines.ThemedianTMBintumor tissuewasobtainedfrom
previously published comprehensive genomic profiling.2,3
Lastly,weonlyconsideredcancers forwhich therewereat least
100 cases of adverse events during anti–PD-1 therapy reported
in FAERS. To assess the risk of a patient developing any irAE,
we estimated reporting odds ratios (RORs) by comparing the
oddsofreportingthese irAEsrather thanothers for theanti–PD-1
agentswith the odds for all other drugs in the database,which
represents standard practice for quantitative analyses of data
in FAERS and similar databases.4
Results | Our search strategy identified a total of 47 304 ad-
verse events (AEs) in 16 397 patients reported as treated with
anti–PD-1monotherapy for 19different cancer types.Of these
patients, 3661hadat least 1 irAE (22.3%;95%CI, 21.7-23.0).The
comparator group comprised 16 411 749 AE reports from
5 160064 patients. Our analysis revealed a significant posi-
tive correlation between the ROR of reporting an irAE during
anti–PD-1 therapy and the corresponding TMB across mul-
tiple cancer types, with a higher ROR of irAE associated with
a higher median number of coding somatic mutations per
megabase of DNA (Figure; Pearson correlation coefficient
Figure. Association of TumorMutational BurdenWith Immune-Related Adverse Events During Anti–PD-1
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The x-axis indicates the tumor
mutational burden (TMB)—defined as
themedian number of coding
somatic mutations per megabase of
DNA—across 19 cancer types. Data on
the x-axis are presented on a
logarithmic scale. The y-axis shows
the reporting odds ratio of any
immune-related adverse event (irAE)
across cancer types, calculated using
data from the US Food and Drug
Administration Adverse Event
Reporting System (FAERS) database.
The dashed line represents the 95%
CI of the linear fit. Circle size
represents the total number of FAERS
cases for each cancer type, and the
color indicates the total number of
tumor samples used tomeasure TMB
for each cancer type.
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R = 0.704;P < .001). The correlation coefficient suggests that
50%of thedifferences in the irAE risk across cancer typesmay
be attributed to the TMB.
Discussion |Ouranalysis indicates thatcancerswithahighTMB,
such as melanoma and non–small cell lung cancer, are asso-
ciated with a higher irAE ROR during anti–PD-1 therapy,
strongly suggesting that these cancers are associated with a
higher risk of irAEs than cancers with a low TMB. A possible
explanation for this finding may be the different neoanti-
genic load across cancer types. Additionally, studies have
shown that T cells that react against a neoantigen can cross-
react against the corresponding wild-type protein.5 Another
contributingmechanismmaybe antigen spreading,where tu-
mor cell death releases antigens, including neoantigens, that
prime lymphocytes against thewild-type antigens in healthy
tissue. Given the results of the analysis, we propose that the
association between irAEs and improved response to anti–
PD-1 treatment are linked via an underlying neoantigenic po-
tential that stems from a high TMB. A limitation of the study
is theuse of spontaneous reports for indirectlymeasuring the
risk of irAE. Furthermore, patients with cancers with a high
TMBmay receive a longer courseof anti–PD-1 treatment.How-
ever, most irAEs reported during anti–PD-1 therapy develop
within the first few weeks of treatment.6 This finding sug-
gests that therapy duration is unlikely to influence the statis-
tical outcome. In conclusion, a high TMBmay be a useful bio-
marker for assessing patients’ risk of irAEs during anti–PD-1
therapy, which has particular relevance for vulnerable pa-
tient groups.
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